Horizon Pharma Inc., An Overvalued And Over-Hyped Company Performing A Questionable Acquisition To Mask Deteriorating Organic Revenue Growth.
These notes are about Horizon Pharma Inc. (NasdaqGS: HZNP) currently trading at $14.42
See you in the sub $10 LEVEL ...
PART 1: THE QUESTIONABLE VIDARA ACQUISITION (stay tuned for PART II)
Why would you value $704m something (VIDATE/Actimmune) that 2 years ago had been sold for $55.0 million in cash, plus certain (minimal) conditional royalty payments ?
At closing of the VIDARA Acquisition there will be approximately be 122 million fully-dilute shares. At current HZNP ($14.30) shares prices this implies a $1,744.6m valuation for the Company's Equity. This transaction will also add approximately $200m ++ in debt to the already present $112.7m net convertible debt and $313.4m Derivative liabilities HZNP had on its Balance sheet as of March 31, 2014.
Do you really think HZNP real value is that high?
I DO NOT THINK SO ... & ... THIS IS WHY I DECIDED TO SHARE MY PERSONAL NOTES WITH YOU in the coming months ...
unemon.com/ResearchEasy/20140723_HZNP_Pa...
Disclosure: The author is short HZNP.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.